Partnership covers oncology, respiratory diseases, inflammation, and autoimmune diseases.
MedImmune, the French National Institute of Health and Medical Research (Inserm), and its private technology-transfer subsidiary Inserm Transfert will advance research in oncology, respiratory diseases, inflammation, and autoimmune diseases under a three-year collaboration.
MedImmune, the biologics business of AstraZeneca, says it will fund both preclinical and clinical research projects to be carried out with Inserm. The projects will explore translational medicine and new disease mechanisms as well as identify promising approaches to advance drug candidates for patients with unmet medical needs.
The collaboration will launch with 10 research projects using Inserm’s physician-biologist teams. A joint steering committee (JSC) is evaluating and will decide additional research projects.
MedImmune is one of 10 strategic partners among the 500 collaborators of Inserm, which took on responsibility for the strategic, scientific, and operational coordination of biomedical research three years ago. Founded in 1964, Inserm has operations in 316 laboratories, with 54 clinical investigation centers and a strong association with universities and hospitals.